Literature DB >> 31527070

Direct Detection and Quantification of Neoantigens.

Qing Wang1,2, Jacqueline Douglass3,2, Michael S Hwang3,2, Emily Han-Chung Hsiue3,2, Brian J Mog3,2, Ming Zhang3,2, Nickolas Papadopoulos3,2, Kenneth W Kinzler3,2, Shibin Zhou1,2, Bert Vogelstein1,2.   

Abstract

Many immunotherapeutic approaches under development rely on T-cell recognition of cancer-derived peptides bound to human leukocyte antigen molecules on the cell surface. Direct experimental demonstration that such peptides are processed and bound is currently challenging. Here, we describe a method that meets this challenge. The method entailed an optimized immunoprecipitation protocol coupled with two-dimensional chromatography and mass spectrometry. The ability to detect and quantify minute amounts of predefined antigens should be useful both for basic research in tumor immunology and for the development of rationally designed cancer vaccines. ©2019 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 31527070      PMCID: PMC6825591          DOI: 10.1158/2326-6066.CIR-19-0107

Source DB:  PubMed          Journal:  Cancer Immunol Res        ISSN: 2326-6066            Impact factor:   11.151


  28 in total

1.  Soluble plasma HLA peptidome as a potential source for cancer biomarkers.

Authors:  Michal Bassani-Sternberg; Eilon Barnea; Ilan Beer; Irit Avivi; Tami Katz; Arie Admon
Journal:  Proc Natl Acad Sci U S A       Date:  2010-10-25       Impact factor: 11.205

2.  Precipitation techniques.

Authors:  S Englard; S Seifter
Journal:  Methods Enzymol       Date:  1990       Impact factor: 1.600

3.  Mutational and putative neoantigen load predict clinical benefit of adoptive T cell therapy in melanoma.

Authors:  Martin Lauss; Marco Donia; Katja Harbst; Rikke Andersen; Shamik Mitra; Frida Rosengren; Maryem Salim; Johan Vallon-Christersson; Therese Törngren; Anders Kvist; Markus Ringnér; Inge Marie Svane; Göran Jönsson
Journal:  Nat Commun       Date:  2017-11-23       Impact factor: 14.919

4.  Neoantigen prediction and the need for validation.

Authors:  Antonella Vitiello; Maurizio Zanetti
Journal:  Nat Biotechnol       Date:  2017-09-11       Impact factor: 54.908

5.  Mutant proteins as cancer-specific biomarkers.

Authors:  Qing Wang; Raghothama Chaerkady; Jian Wu; Hee Jung Hwang; Nick Papadopoulos; Levy Kopelovich; Anirban Maitra; Hanno Matthaei; James R Eshleman; Ralph H Hruban; Kenneth W Kinzler; Akhilesh Pandey; Bert Vogelstein
Journal:  Proc Natl Acad Sci U S A       Date:  2011-01-19       Impact factor: 11.205

6.  Targeting of cancer neoantigens with donor-derived T cell receptor repertoires.

Authors:  Erlend Strønen; Mireille Toebes; Sander Kelderman; Marit M van Buuren; Weiwen Yang; Nienke van Rooij; Marco Donia; Maxi-Lu Böschen; Fridtjof Lund-Johansen; Johanna Olweus; Ton N Schumacher
Journal:  Science       Date:  2016-05-19       Impact factor: 47.728

7.  An immunogenic personal neoantigen vaccine for patients with melanoma.

Authors:  Patrick A Ott; Zhuting Hu; Derin B Keskin; Sachet A Shukla; Jing Sun; David J Bozym; Wandi Zhang; Adrienne Luoma; Anita Giobbie-Hurder; Lauren Peter; Christina Chen; Oriol Olive; Todd A Carter; Shuqiang Li; David J Lieb; Thomas Eisenhaure; Evisa Gjini; Jonathan Stevens; William J Lane; Indu Javeri; Kaliappanadar Nellaiappan; Andres M Salazar; Heather Daley; Michael Seaman; Elizabeth I Buchbinder; Charles H Yoon; Maegan Harden; Niall Lennon; Stacey Gabriel; Scott J Rodig; Dan H Barouch; Jon C Aster; Gad Getz; Kai Wucherpfennig; Donna Neuberg; Jerome Ritz; Eric S Lander; Edward F Fritsch; Nir Hacohen; Catherine J Wu
Journal:  Nature       Date:  2017-07-05       Impact factor: 49.962

8.  Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer.

Authors:  Ugur Sahin; Evelyna Derhovanessian; Matthias Miller; Björn-Philipp Kloke; Petra Simon; Martin Löwer; Valesca Bukur; Arbel D Tadmor; Ulrich Luxemburger; Barbara Schrörs; Tana Omokoko; Mathias Vormehr; Christian Albrecht; Anna Paruzynski; Andreas N Kuhn; Janina Buck; Sandra Heesch; Katharina H Schreeb; Felicitas Müller; Inga Ortseifer; Isabel Vogler; Eva Godehardt; Sebastian Attig; Richard Rae; Andrea Breitkreuz; Claudia Tolliver; Martin Suchan; Goran Martic; Alexander Hohberger; Patrick Sorn; Jan Diekmann; Janko Ciesla; Olga Waksmann; Alexandra-Kemmer Brück; Meike Witt; Martina Zillgen; Andree Rothermel; Barbara Kasemann; David Langer; Stefanie Bolte; Mustafa Diken; Sebastian Kreiter; Romina Nemecek; Christoffer Gebhardt; Stephan Grabbe; Christoph Höller; Jochen Utikal; Christoph Huber; Carmen Loquai; Özlem Türeci
Journal:  Nature       Date:  2017-07-05       Impact factor: 49.962

9.  Early Kinetics of the HLA Class I-Associated Peptidome of MVA.HIVconsv-Infected Cells.

Authors:  Nicola Ternette; Peter D Block; Álvaro Sánchez-Bernabéu; Nicola Borthwick; Elisa Pappalardo; Sultan Abdul-Jawad; Beatrice Ondondo; Philip D Charles; Lucy Dorrell; Benedikt M Kessler; Tomáš Hanke
Journal:  J Virol       Date:  2015-03-25       Impact factor: 5.103

10.  Selected reaction monitoring for quantitative proteomics: a tutorial.

Authors:  Vinzenz Lange; Paola Picotti; Bruno Domon; Ruedi Aebersold
Journal:  Mol Syst Biol       Date:  2008-10-14       Impact factor: 11.429

View more
  14 in total

Review 1.  Targeting public neoantigens for cancer immunotherapy.

Authors:  Alexander H Pearlman; Michael S Hwang; Maximilian F Konig; Emily Han-Chung Hsiue; Jacqueline Douglass; Sarah R DiNapoli; Brian J Mog; Chetan Bettegowda; Drew M Pardoll; Sandra B Gabelli; Nicholas Papadopoulos; Kenneth W Kinzler; Bert Vogelstein; Shibin Zhou
Journal:  Nat Cancer       Date:  2021-05-17

2.  Combined presentation and immunogenicity analysis reveals a recurrent RAS.Q61K neoantigen in melanoma.

Authors:  Aviyah Peri; Erez Greenstein; Michal Alon; Joy A Pai; Tamir Dingjan; Shlomit Reich-Zeliger; Eilon Barnea; Chaya Barbolin; Ronen Levy; Claudia Arnedo-Pac; Shelly Kalaora; Bareket Dassa; Ester Feldmesser; Ping Shang; Polina Greenberg; Yishai Levin; Gil Benedek; Mitchell P Levesque; David J Adams; Michal Lotem; James S Wilmott; Richard A Scolyer; Göran B Jönsson; Arie Admon; Steven A Rosenberg; Cyrille J Cohen; Masha Y Niv; Nuria Lopez-Bigas; Ansuman T Satpathy; Nir Friedman; Yardena Samuels
Journal:  J Clin Invest       Date:  2021-10-15       Impact factor: 14.808

Review 3.  1,2,3, MHC: a review of mass-spectrometry-based immunopeptidomics methods for relative and absolute quantification of pMHCs.

Authors:  L E Stopfer; A D D'Souza; F M White
Journal:  Immunooncol Technol       Date:  2021-10-13

4.  Bispecific antibodies targeting mutant RAS neoantigens.

Authors:  Jacqueline Douglass; Emily Han-Chung Hsiue; Brian J Mog; Michael S Hwang; Sarah R DiNapoli; Alexander H Pearlman; Michelle S Miller; Katharine M Wright; P Aitana Azurmendi; Qing Wang; Suman Paul; Annika Schaefer; Andrew D Skora; Marco Dal Molin; Maximilian F Konig; Qiang Liu; Evangeline Watson; Yana Li; Michael B Murphy; Drew M Pardoll; Chetan Bettegowda; Nickolas Papadopoulos; Sandra B Gabelli; Kenneth W Kinzler; Bert Vogelstein; Shibin Zhou
Journal:  Sci Immunol       Date:  2021-03-01

5.  Targeting a neoantigen derived from a common TP53 mutation.

Authors:  Emily Han-Chung Hsiue; Katharine M Wright; Jacqueline Douglass; Michael S Hwang; Brian J Mog; Alexander H Pearlman; Suman Paul; Sarah R DiNapoli; Maximilian F Konig; Qing Wang; Annika Schaefer; Michelle S Miller; Andrew D Skora; P Aitana Azurmendi; Michael B Murphy; Qiang Liu; Evangeline Watson; Yana Li; Drew M Pardoll; Chetan Bettegowda; Nickolas Papadopoulos; Kenneth W Kinzler; Bert Vogelstein; Sandra B Gabelli; Shibin Zhou
Journal:  Science       Date:  2021-03-01       Impact factor: 47.728

Review 6.  Empirical and Rational Design of T Cell Receptor-Based Immunotherapies.

Authors:  Heather F Jones; Zaki Molvi; Martin G Klatt; Tao Dao; David A Scheinberg
Journal:  Front Immunol       Date:  2021-01-25       Impact factor: 7.561

7.  Biochemical and functional characterization of mutant KRAS epitopes validates this oncoprotein for immunological targeting.

Authors:  Adham S Bear; Tatiana Blanchard; Joseph Cesare; Michael J Ford; Lee P Richman; Chong Xu; Miren L Baroja; Sarah McCuaig; Christina Costeas; Khatuna Gabunia; John Scholler; Avery D Posey; Mark H O'Hara; Anze Smole; Daniel J Powell; Benjamin A Garcia; Robert H Vonderheide; Gerald P Linette; Beatriz M Carreno
Journal:  Nat Commun       Date:  2021-07-16       Impact factor: 17.694

Review 8.  Exploiting Tumor Neoantigens to Target Cancer Evolution: Current Challenges and Promising Therapeutic Approaches.

Authors:  Ravi G Gupta; Fenge Li; Jason Roszik; Gregory Lizée
Journal:  Cancer Discov       Date:  2021-03-15       Impact factor: 38.272

9.  Multiplexed relative and absolute quantitative immunopeptidomics reveals MHC I repertoire alterations induced by CDK4/6 inhibition.

Authors:  Lauren E Stopfer; Joshua M Mesfin; Brian A Joughin; Douglas A Lauffenburger; Forest M White
Journal:  Nat Commun       Date:  2020-06-02       Impact factor: 14.919

Review 10.  T-Cell Receptor Mimic Antibodies for Cancer Immunotherapy.

Authors:  Zhijian Duan; Mitchell Ho
Journal:  Mol Cancer Ther       Date:  2021-06-25       Impact factor: 6.009

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.